Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations

[1]  J. Stenvang,et al.  Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance , 2015, Molecular oncology.

[2]  A. Desideri,et al.  Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico , 2013, Molecular Cancer.

[3]  H. Nielsen,et al.  Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort , 2013, PloS one.

[4]  Y. Pommier.  Drugging topoisomerases: lessons and challenges. , 2013, ACS chemical biology.

[5]  Yvonne A. Evrard,et al.  Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues , 2012, PloS one.

[6]  Y. Pommier,et al.  Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase I poisons. , 2012, Journal of medicinal chemistry.

[7]  N. Brünner,et al.  Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer , 2012, Scandinavian journal of gastroenterology.

[8]  B. Glimelius,et al.  Metastatic colorectal cancer: Current treatment and future options for improved survival Medical approach – present status , 2012, Scandinavian journal of gastroenterology.

[9]  H. Nielsen,et al.  TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity , 2012, Scandinavian journal of gastroenterology.

[10]  I. Gelissen,et al.  The ABCG family of membrane‐associated transporters: you don't have to be big to be mighty , 2011, British journal of pharmacology.

[11]  C. Hsieh,et al.  The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. , 2011, Molecular pharmaceutics.

[12]  A. Causse,et al.  New Topoisomerase I mutations are associated with resistance to camptothecin , 2011, Molecular Cancer.

[13]  R. Gjerset,et al.  Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. , 2011, Biochemistry.

[14]  Yves Pommier,et al.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. , 2010, Chemistry & biology.

[15]  E. Van Cutsem,et al.  Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Felicie F. Andersen,et al.  Multiplexed detection of site specific recombinase and DNA topoisomerase activities at the single molecule level. , 2009, ACS nano.

[17]  I. Nagtegaal,et al.  6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG) , 2009 .

[18]  W. Reinhold,et al.  Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity , 2009, Molecular Cancer Therapeutics.

[19]  I. Nagtegaal,et al.  A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? , 2009, European journal of cancer.

[20]  J. Nitiss.  Targeting DNA topoisomerase II in cancer chemotherapy , 2009, Nature Reviews Cancer.

[21]  Y. Pommier,et al.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives , 2009, Molecular Cancer Therapeutics.

[22]  Felicie F. Andersen,et al.  Single-molecule detection of human topoisomerase I cleavage-ligation activity. , 2009, ACS nano.

[23]  M. Watson,et al.  Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. , 2008, Pharmacogenomics.

[24]  G. Chillemi,et al.  A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance , 2008, Nucleic acids research.

[25]  W. Richard McCombie,et al.  Topoisomerase levels determine chemotherapy response in vitro and in vivo , 2008, Proceedings of the National Academy of Sciences.

[26]  J. Barrett,et al.  Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Teicher.  Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. , 2008, Biochemical pharmacology.

[28]  M. Bjornsti,et al.  Mutation of Gly721 Alters DNA Topoisomerase I Active Site Architecture and Sensitivity to Camptothecin* , 2008, Journal of Biological Chemistry.

[29]  Y. Pommier,et al.  Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. , 2007, Cancer research.

[30]  J. Weinstein,et al.  Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. , 2007, Cancer research.

[31]  Richard J Stephens,et al.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.

[32]  Linda Mol,et al.  Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2007, The Lancet.

[33]  M. Bjornsti,et al.  Alterations in Linker Flexibility Suppress DNA Topoisomerase I Mutant-induced Cell Lethality* , 2007, Journal of Biological Chemistry.

[34]  H. Lenz,et al.  Molecular determinants of irinotecan efficacy , 2006, International journal of cancer.

[35]  F. Zunino,et al.  Mechanisms of cellular resistance to camptothecins. , 2006, Current medicinal chemistry.

[36]  Hisashi Yamada,et al.  Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells , 2006, Molecular Cancer Therapeutics.

[37]  M. Valerio,et al.  Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[39]  A. Paradiso,et al.  Topoisomerase‐I, thymidylate synthase primary tumour expression and clinical efficacy of 5‐FU/CPT‐11 chemotherapy in advanced colorectal cancer patients , 2004, International journal of cancer.

[40]  Yves Pommier,et al.  Mechanisms of camptothecin resistance by human topoisomerase I mutations. , 2004, Journal of molecular biology.

[41]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Saltz,et al.  The camptothecins , 2003, The Lancet.

[43]  Masahiro Fukuoka,et al.  Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. , 2002, Lung cancer.

[44]  C. Bailly,et al.  Active Site Mutations in DNA Topoisomerase I Distinguish the Cytotoxic Activities of Camptothecin and the Indolocarbazole, Rebeccamycin* , 2002, The Journal of Biological Chemistry.

[45]  Y. Pommier,et al.  Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. , 2001, Cancer research.

[46]  Y. Pommier,et al.  Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate* , 2000, The Journal of Biological Chemistry.

[47]  M. Bjornsti,et al.  Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. , 1999, Molecular pharmacology.

[48]  Yves Pommier,et al.  Topoisomerase I inhibitors: selectivity and cellular resistance. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[49]  A. Fojo,et al.  Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. , 1997, Cancer research.

[50]  L. Liu,et al.  Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. , 1997, Biochemical pharmacology.

[51]  G. Giaccone,et al.  CPT‐11 in human colon‐cancer cell lines and xenografts: Characterization of cellular sensitivity determinants , 1997, International journal of cancer.

[52]  H. McLeod,et al.  Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. , 1996, British Journal of Cancer.

[53]  M. Sehested,et al.  Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. , 1995, British Journal of Cancer.

[54]  M. Bjornsti,et al.  A Camptothecin-resistant DNA Topoisomerase I Mutant Exhibits Altered Sensitivities to Other DNA Topoisomerase Poisons (*) , 1995, The Journal of Biological Chemistry.

[55]  F. Zunino,et al.  Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. , 1994, Anti-cancer drugs.

[56]  K. Kohno,et al.  Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. , 1994, Cancer research.

[57]  D. Kufe,et al.  Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. , 1994, The Journal of biological chemistry.

[58]  J. Wang,et al.  Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. , 1993, Cancer research.

[59]  R. Demicheli,et al.  Drugs ten years later: epirubicin. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  G. Riou,et al.  Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. , 1993, Biochemical pharmacology.

[61]  N. Saijo,et al.  Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. , 1992, Biochemical and biophysical research communications.

[62]  T. Tsuruo,et al.  Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. , 1990, Cancer research.

[63]  T. Tsuruo,et al.  Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. , 1990, Cancer research.

[64]  K. Kohn,et al.  Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. , 1989, Cancer research.

[65]  J. Wang,et al.  DNA topoisomerase-targeting antitumor drugs can be studied in yeast. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[66]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[67]  Y. Pommier.  DNA Topoisomerases and Cancer , 2012 .

[68]  J. Champoux.  DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.

[69]  Y. Pommier,et al.  Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. , 1996, Oncology research.